Table 1 Baseline characteristics of ex-/non-smokers (n = 39)
From: Ambulatory pulse oximetry monitoring in Japanese COPD outpatients not receiving oxygen therapy
Age (years) | Mean ± SD | 71.6 ± 8.8 |
Sex | Male/female | 36/3 |
Smoking pack/years | Mean ± SD | 68.2 ± 33.4 |
BMI (kg/m2) | Mean ± SD | 23.1 ± 3.8 |
Underweight (BMI < 18.5 kg/m2) | n (%) | 4 (10.3) |
Overweight (BMI 25–30 kg/m2) | n (%) | 5 (12.8) |
Obese (BMI ≥ 30 kg/m2) | n (%) | 2 (5.1) |
Unadjusted Charlson Comorbidity Index | Median (range) | 1 (0–4) |
Age-adjusted Charlson Comorbidity Index | Median (range) | 5 (2–9) |
Treatment | ||
Long-acting muscarinic antagonist | n (%) | 26 (67%) |
Long-acting β2 agonist | n (%) | 27 (69%) |
Inhaled corticosteroid | n (%) | 27 (69%) |
PaO2 (mmHg) | Mean ± SD | 78.2 ± 8.9 |
PaCO2 (mmHg) | Mean ± SD | 39.1 ± 4.9 |
GOLD stage | I/II/III/IV | 2/18/13/6 |
FEV1 (L) | Mean ± SD | 1.3 ± 0.6 |
FEV1 (%predicted) | Mean ± SD | 50.9 ± 18.5 |
FVC (L) | Mean ± SD | 2.3 ± 1.0 |
mMRC dyspnoea grade | Mean ± SD | 2.2 ± 1.1 |
Median (range) | 2 (0–4) | |
CAT score | Mean ± SD | 11.7 ± 7.0 |
Median (range) | 10 (0–29) |